Oncolytics Biotech Inc. (ONCY)

Market Cap	77.05M
Revenue (ttm)	n/a
Net Income (ttm)	-20.46M
Shares Out	77.07M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	274,064
Open	1.070
Previous Close	1.060
Day's Range	0.986 - 1.070
52-Week Range	0.840 - 1.750
Beta	1.51
Analysts	Strong Buy
Price Target	4.00 (+300.6%)
Earnings Date	Nov 12, 2024

About ONCY

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelare...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 1999
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCY
• Website: https://www.oncolyticsbiotech.com

Financial Performance

Financial numbers in CAD

Analyst Forecast

According to 2 analysts, the average rating for ONCY stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 300.60% from the latest price.

Price Target

$4.0

(300.60% upside)

Analyst Consensus: Strong Buy